Aquestive Therapeutics (AQST) to Release Earnings on Wednesday

Aquestive Therapeutics (NASDAQ:AQST) is expected to issue its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $13.2840 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:00 AM ET.

Aquestive Therapeutics Stock Performance

NASDAQ AQST opened at $4.09 on Wednesday. Aquestive Therapeutics has a 52 week low of $2.12 and a 52 week high of $7.55. The stock’s 50 day moving average price is $4.49 and its two-hundred day moving average price is $5.20. The stock has a market capitalization of $498.98 million, a price-to-earnings ratio of -5.76 and a beta of 1.65.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. PharVision Advisers LLC bought a new stake in Aquestive Therapeutics in the third quarter valued at approximately $260,000. Intech Investment Management LLC increased its holdings in shares of Aquestive Therapeutics by 58.9% during the 4th quarter. Intech Investment Management LLC now owns 33,913 shares of the company’s stock worth $219,000 after acquiring an additional 12,566 shares during the last quarter. Jane Street Group LLC bought a new stake in Aquestive Therapeutics in the 2nd quarter valued at $217,000. Man Group plc bought a new stake in Aquestive Therapeutics in the 4th quarter valued at $189,000. Finally, Quarry LP acquired a new stake in Aquestive Therapeutics during the 3rd quarter valued at $181,000. 32.45% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on AQST. Wall Street Zen lowered shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Finally, Piper Sandler raised their price objective on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.50.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.